Overzicht:

Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach

TitleComparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach
Publication TypeOther Journal Article
Year of Publication2009
AuthorsDe Ridder, A., & De Graeve D.
JournalPharmacoeconomics
Volume27
Issue1
Pagination69-80
Universiteit Antwerpen - University of Antwerp
Centrum voor Sociaal Beleid © 2005 - 2020